Last reviewed · How we verify
FluMist live attenuated influenza vaccine
FluMist, a live attenuated influenza vaccine marketed by Richard Zimmerman MD, holds a distinct position in the influenza vaccine market. A key strength is its key composition patent, which is set to expire in 2028, providing a period of exclusivity. The primary risk is the lack of specified revenue data, which may impact financial forecasting and market valuation.
At a glance
| Generic name | FluMist live attenuated influenza vaccine |
|---|---|
| Sponsor | Richard Zimmerman MD |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Vaccine Pandemic Preparedness Through Airway Immunology Characterization (EARLY_PHASE1)
- Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD) (EARLY_PHASE1)
- Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection (PHASE4)
- Administration of the Nasal Influenza Vaccine to Children in Daycare or at a Healthcare Facility (NA)
- Bacterial Composition and Immune Responses in the Nose and Oropharynx During Influenza Infection (PHASE1)
- Intranasal LAIV Mucosal Immunity Examination (PHASE4)
- The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study (PHASE4)
- Mucosal and Systemic Immune Responses Induced by an Intranasal Influenza Live Attenuated Vaccine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: